Galectin Therapeutics Inc.

GALT Healthcare Biotechnology

In the quarter to June 2026, EPS fell 16.7%, free cash flow grew 63.1% and total debt fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.62 0.09 −2.43%
Market cap
$374.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Current Ratio
2.42 0.49 1.77 1.58 4.63 5.46 17.10 4.19 1.29 4.18
Net Debt/EBITDA
(5.79) (1.65) (1.21) (0.55) 0.35 1.16 3.54 0.61 0.19 0.72
Debt/Assets
684.70% 486.48% 254.40% 187.12% 69.45% 0.03% 0.11% 0.00% 0.00% 0.00%
Debt/Equity
(1.06) (0.83) (1.19) (1.24) 11.10 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
0.77 0.88 0.74 0.80 0.79 0.87 0.54 0.68 0.91 0.73
Capex/Depreciation
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00
Interest Coverage
(2.74) (7.66) (13.64) (37.13) (61.72) (269.47) (154.46) (40.48) (1,353.92) (477.36)
ROE
26.51% 56.27% 92.49% 228.26% (275.21%) (72.31%) (97.74%) 306.67% 740.75% (217.67%)
ROA
(167.30%) (206.59%) (181.09%) (123.19%) (85.96%) (60.47%) (70.22%) (228.56%) (175.06%) (105.92%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(271.56%) 259.95% (372.32%) (515.56%) (93.63%) (98.07%) (44.46%) (223.78%) (2,052.53%) (186.03%)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.37) (0.67) (0.55) (0.52) (0.42) (0.36) (0.21) (0.26) (0.45) (0.56)
Cash per Share
0.28 0.24 0.43 0.31 0.68 0.48 0.91 0.21 0.09 0.53
Shareholders Equity per Share
(1.97) (1.65) (1.00) (0.54) 0.04 0.42 0.87 0.18 0.03 0.41
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(1.97) (1.65) (1.00) (0.54) 0.04 0.42 0.87 0.18 0.03 0.41
Free Cash Flow
(23.87) (41.77) (32.96) (31.06) (24.31) (20.60) (10.85) (10.18) (15.89) (16.41)
Working Capital
11.41 (18.16) 12.03 7.54 32.79 24.07 45.39 6.72 0.85 12.01
Net Current Asset Value
(126.29) (103.31) (60.73) (32.93) 2.61 24.06 45.34 6.72 0.85 12.01
Other line items
Quick Ratio
2.21 0.43 1.64 1.43 4.39 5.03 16.84 3.92 1.03 4.06
Depreciation/Fixed assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00
Cash ROIC
(94.52%) 1,470.15% (88.71%) (118.42%) (34.09%) (40.12%) (11.65%) (67.18%) (374.28%) (59.94%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 0.00 0.00 0.00 — 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 0.00 0.00 0.00 — 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
(0.37) (0.67) (0.55) (0.52) (0.42) (0.36) (0.21) (0.26) (0.45) (0.56)
Capex per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Payables
4.45 6.04 5.16 2.85 1.55 1.48 0.98 0.45 0.76 0.68
Average Assets
18.51 22.85 24.74 31.56 35.71 39.03 28.74 6.58 9.98 21.10
Average Common Equity
(116.85) (83.88) (48.45) (17.03) 11.15 32.64 20.65 (4.91) (2.36) 10.27

Fold the line items

Columns are period end dates